Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Rohto Pharmaceutical Co ( (JP:4527) ) has issued an update.
Rohto Pharmaceutical Co., Ltd. has announced the acquisition of OBAGI-related trademarks in Japan from OBAGI COSMECEUTICALS LLC, a subsidiary of Waldencast plc, for USD 82.5 million. This strategic move allows Rohto to permanently secure licensing and sales rights for OBAGI products in Japan, aiming to strengthen its domestic market position and expand into new channels such as medical clinics.
The most recent analyst rating on (JP:4527) stock is a Buy with a Yen2684.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, known for its diverse range of products including eye care, gastrointestinal products, and skincare. The company has made significant strides in the functional cosmetics sector, particularly with its flagship Obagi brand, which has been a major contributor to its growth and market presence.
Average Trading Volume: 641,393
Technical Sentiment Signal: Sell
Current Market Cap: Yen560.7B
See more insights into 4527 stock on TipRanks’ Stock Analysis page.